Investigate / ELV
Understand Elevance Health, Inc.
Can Elevance price and manage medical costs accurately enough, given premiums are set well before actual costs are known?
Snapshot reviewed 2026-10-02. Source published 2026-07-15. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / ELV
Ask better questions. Keep the evidence.
Explore the available sources for Elevance Health, Inc., then keep what deserves another look.
01 Investor activity
Who reports owning ELV?
11 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
Customers pay Elevance for risk-based health plan premiums, administrative fees from self-funded employers, and pharmacy and health service fees through its Carelon businesses.
Latticework interpretation
What could support the case?
If local market focus and national scale support effective value-based payment programs, Elevance’s provider collaborations could help deliver cost-effective care.
Latticework interpretation
What could break the case?
If actual medical costs exceed projections, Elevance cannot recover those excess costs through higher premiums in the contract year, which could harm results.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Customers pay Elevance for risk-based health plan premiums, administrative fees from self-funded employers, and pharmacy and health service fees through its Carelon businesses.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps or explicitly source-reviewed exclusions, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $50,474m | $49,776m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $1,463m | $1,743m |
| Operating cash flow ↗Six months (year to date): 2026-01-01–2026-06-30; prior 2025-01-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $6,245m | $3,071m |
Comparison caveat: Operating cash covers the half-year and the increase primarily reflects favorable working-capital effects, partly offset by lower net income. Cash growth is not simply growth in recurring earnings.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If local market focus and national scale support effective value-based payment programs, Elevance’s provider collaborations could help deliver cost-effective care.
Supporting filing ↗The strongest caution
If actual medical costs exceed projections, Elevance cannot recover those excess costs through higher premiums in the contract year, which could harm results.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How are elevated medical cost trends developing?
Starting evidence: Membership shifts and lower effectuation have driven higher morbidity and elevated medical cost trends, which may pressure results if pricing lags.
Investigate next: Review later filings for medical cost trend commentary and whether management says pricing has caught up to Individual ACA and Medicaid cost levels.
Read the supporting filing ↗Is Medicare and Medicaid pricing keeping pace with costs?
Starting evidence: Government program pricing may not adequately reflect current healthcare cost trends because of the timing lag before contracts start, which could adversely affect financial results.
Investigate next: Compare disclosed Medicare bid and Medicaid rate-setting timing against reported cost trends and any rate adjustments or delays.
Read the supporting filing ↗How exposed is the Public Exchange business to rule changes?
Starting evidence: Public Exchange markets are described as volatile, and changes including expiration of enhanced subsidies could make actual market behavior differ from premium-setting assumptions.
Investigate next: Examine Individual ACA membership, acuity and subsidy assumptions in the latest filings and verify subsequent policy developments.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.